The Effects of the Telomerase Activator TA-65 on Insulin Resistance, Inflammation, and Metabolic Syndrome
Latest Information Update: 18 Sep 2021
At a glance
- Drugs TA 65 (Primary)
- Indications Metabolic syndrome
- Focus Therapeutic Use
- 28 May 2015 Biomarkers information updated
- 21 Jan 2013 New trial record